Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

Citi initiated coverage of Moderna (MRNA) with a Neutral rating and $40 price target Healthcare policy remains a key biopharma sector ...

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Just a couple months ago, between October 2024 and December 2024, an estimated 72,000 to 120,000 people were hospitalized due to COVID-19, underscoring the crit ...

Moderna Inc., a biotechnology and pharmaceutical company reorienting its business for a post-pandemic age, awarded almost $17 ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...